Krawczyk A, Sladowska G, Strzalka-Mrozik B
Cancers (Basel). 2025; 17(5).
PMID: 40075568
PMC: 11899293.
DOI: 10.3390/cancers17050719.
Hong J, Choi R, Shim J, Kim K, Kim R, Cho H
Neuro Oncol. 2024; 27(3):654-667.
PMID: 39392921
PMC: 11889716.
DOI: 10.1093/neuonc/noae211.
Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K
J Med Chem. 2022; 65(13):8596-8685.
PMID: 35786935
PMC: 9297300.
DOI: 10.1021/acs.jmedchem.1c01946.
Otreba M, Stojko J, Kabala-Dzik A, Rzepecka-Stojko A
Oncol Lett. 2022; 23(6):182.
PMID: 35527777
PMC: 9073583.
DOI: 10.3892/ol.2022.13302.
Wang Y, Chen W, Shi Y, Yan C, Kong Z, Wang Y
Front Oncol. 2021; 11:719623.
PMID: 34568049
PMC: 8458950.
DOI: 10.3389/fonc.2021.719623.
Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.
Liu Y, Huang B, Lin C, Shen C, Lai S, Chen C
Cancers (Basel). 2021; 13(17).
PMID: 34503167
PMC: 8430966.
DOI: 10.3390/cancers13174357.
Neuro-Signals from Gut Microbiota: Perspectives for Brain Glioma.
DAlessandro G, Lauro C, Quaglio D, Ghirga F, Botta B, Trettel F
Cancers (Basel). 2021; 13(11).
PMID: 34199968
PMC: 8200200.
DOI: 10.3390/cancers13112810.
Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.
Williford S, Libby C, Ayokanmbi A, Otamias A, Gordillo J, Gordon E
PLoS One. 2021; 16(5):e0250649.
PMID: 33945569
PMC: 8096095.
DOI: 10.1371/journal.pone.0250649.
Involvement of the Catecholamine Pathway in Glioblastoma Development.
Kraboth Z, Kajtar B, Galik B, Gyenesei A, Miseta A, Kalman B
Cells. 2021; 10(3).
PMID: 33806345
PMC: 7998903.
DOI: 10.3390/cells10030549.
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu V, Morrow S, Kawakibi A, Zhou L, Ralff M, Ray J
Neoplasia. 2020; 22(12):725-744.
PMID: 33142238
PMC: 7588802.
DOI: 10.1016/j.neo.2020.09.005.
Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer players.
Franceschi S, Lessi F, Aretini P, Ortenzi V, Scatena C, Menicagli M
Oncotarget. 2018; 9(35):24014-24027.
PMID: 29844869
PMC: 5963624.
DOI: 10.18632/oncotarget.25265.
Drug Repositioning in Glioblastoma: A Pathway Perspective.
Tan S, Jermakowicz A, Mookhtiar A, Nemeroff C, Schurer S, Ayad N
Front Pharmacol. 2018; 9:218.
PMID: 29615902
PMC: 5864870.
DOI: 10.3389/fphar.2018.00218.
Anti-cancer effects of dopamine in human glioma: involvement of mitochondrial apoptotic and anti-inflammatory pathways.
Lan Y, Wang X, Xing J, Yu Z, Lou J, Ma X
Oncotarget. 2017; 8(51):88488-88500.
PMID: 29179451
PMC: 5687621.
DOI: 10.18632/oncotarget.19691.
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.
Arrillaga-Romany I, Chi A, Allen J, Oster W, Wen P, Batchelor T
Oncotarget. 2017; 8(45):79298-79304.
PMID: 29108308
PMC: 5668041.
DOI: 10.18632/oncotarget.17837.
PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion.
Gont A, Daneshmand M, Woulfe J, Lavictoire S, Lorimer I
Oncotarget. 2017; 8(5):8559-8573.
PMID: 28051998
PMC: 5352422.
DOI: 10.18632/oncotarget.14348.
Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review.
Faraz S, Pannullo S, Rosenblum M, Smith A, Wernicke A
Ther Adv Med Oncol. 2016; 8(6):421-428.
PMID: 27800031
PMC: 5066542.
DOI: 10.1177/1758834016659791.
